May 6, 2026Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 5, 2026Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
May 5, 2026Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 5, 2026Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseTrial Results • Phase 3
Mar 30, 2026Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye DiseaseTrial Results • Phase 3
Feb 26, 2026Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Dec 22, 2025Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
